Drug Interaction Potentiation
Conditions
Brief summary
This study evaluate the pharmacokinetic drug interactions and safety after co-administration of ilaprazole and Aceclofenac in healthy adults.
Interventions
DRUGIlaprazole
Ilaprazole 10mg
DRUGAceclofenac
Aceclofenac 100mg
Sponsors
Il-Yang Pharm. Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Randomization, Open-label, Repeated administration, Crossover
Eligibility
Sex/Gender
ALL
Age
19 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy adults aged 19 or older and 55 or younger at the time of screening tests. 2. Men weigh more than 55 kg and women weigh more than 50 kg. 3. Those who have a body mass index of 18.5 kg/m2 or more and less than 27.0 kg/m2. ※ Body mass index (kg/m2) = Weight (kg)/\[Height (m)\]2 4. If participants are a woman, participants must apply to one of the following. * Menopausal (no natural menstruation for at least 2 years) * Surgical infertility (autonomous exudation or bilateral ovarian resection, intubation ligation, or other infertility) 5. Men who have sexual relationship with women of child bearing potential must give consent to using contraceptive measures(condoms, spermicide, and menstrual cycle control) for at least 28 days after the final administration of clinical trial and clinical drugs (if the male test subject or female partner is infertile, the above contraception is unnecessary). 6. A person who has heard sufficient explanation of this clinical trial and fully understood it, voluntarily decided to participate, and agreed in writing to comply with precautions.
Exclusion criteria
1. A person with a history of mental illness or illness corresponding to clinically significant hepatobiliary tract (hepatic liver disorder, kidney (severe renal disorder, etc.), nervous system, immune system, respiratory system (bronchial asthma, etc.), urinary system, digestive system, endocrine blood and tumor, cardiovascular system (severe high blood pressure, heart failure, etc.). 2. Active peptic ulcer/bleeding or a person with a medical history. 3. A person who tends to bleed or have a blood clotting disorder. 4. Patients with a history of gastrointestinal bleeding or perforation due to NSAID treatment in the past. 5. Those with a history of gastrointestinal diseases (Crohn's disease, ulcerative colitis, etc.) or surgery (except for simple appendectomy or hernia surgery) that can affect the absorption of drugs. 6. Person with a history of significant drug hypersensitivity reactions to the ingredients and additives of clinical trial drugs. In particular, NSAIDs and aspirin such as Yellow No. 4 (Tartrazine), Yellow No. 5 (Sunset Yellow FCF), sulfonamide, ilaprazole and naproxen, aceclofenac, celecoxib, diclofenac, etc. 7. A person with a history of asthma, rhinitis, and nasal polyps due to aspirin or other NSAIDs (including COX-2 inhibitors). 8. A person who was judged to be inappropriate as a test subject in a screening test conducted within 28 days before the first administration date of the clinical trial drug. * In the case of \> 1.25 times the upper limit of AST and ALT normal range in the blood, * When the potassium concentration in the blood exceeds 5.5 mEq/L, * Estimated Global Film Rate (eGFR) \<60 mL/min/1.73 m2 using the Modification of Diet in Regular Disease (MDRD) formula * Immunology and serology tests (hepatitis B test, hepatitis C test, human immunodeficiency virus (HIV) test, syphilis test) result are positive factors. * After resting for more than 5 minutes, systolic blood pressure \>150 mmHg or \<\< in vital signs measured at the seat\> Those who showed values corresponding to 90 mmHg, dilator blood pressure \>100 mmHg, or \<50 mmHg. 9. A person who has a history of drug abuse or has tested positive in a urine drug screening test within one year of screening. 10. If the tester determines that the following drugs, excluding topical drugs without significant systemic absorption, may affect this test or affect the safety of the test subject within the relevant period, * In the case of taking a prescription drug or herbal medicine within 14 days prior to the first administration date of the clinical trial drug, * In the case of taking general medicines including health foods and vitamin preparations within 7 days prior to the first administration of clinical trial drugs, * A person who took drugs such as barbital drugs and other drugs inducing and inhibiting drugs within 30 days prior to the first administration of clinical trial drugs. 11. A person who continuously smoked excessively or consumed caffeine or alcohol (caffeine: \>5 cups/day, alcohol: \>210 g/week, tobacco: \>10 g/day) or who cannot stop smoking, caffeine and alcohol consumption during each hospitalization period. 12. A person who has consumed grapefruit-containing food within 7 days prior to the first administration date of clinical trial drugs or cannot be prohibited from taking it during the clinical trial period. 13. A person who participated in another clinical trial within 180 days prior to the first administration date of the clinical trial drug and received the clinical trial drug (in the case of biological agents, it may be based on an extended period considering a half-life). 14. A person who donated whole blood within 60 days prior to the first administration date of clinical trial drugs or donated component blood within 30 days. 15. A person who received a blood transfusion within 30 days prior to the first administration date of the clinical trial drug. 16. Pregnant or lactating women. 17. A person who determines that the tester is inappropriate to participate in clinical trials due to other reasons.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ilaprazole, aceclofenac Cmax,ss | Predose(0hour), after dose 0.5hour, 0.75hour, 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours | Maximum concentration of drug in plasma at steady state |
| ilaprazole, aceclofenac AUCtau,ss | Predose(0hour), after dose 0.5hour, 0.75hour, 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours | Area under the plasma drug concentration-time curve within a dosing interval (tau) at steady state |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ilaprazole, aceclofenac Vdss/F | Predose(0hour), after dose 0.5hour, 0.75hour, 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours | Apparent volume of distribution at steady state |
| ilaprazole, aceclofenac Tmax,ss | Predose(0hour), after dose 0.5hour, 0.75hour, 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours | Time to maximum plasma concentration at steady state |
| ilaprazole, aceclofenac fluctuation | Predose(0hour), after dose 0.5hour, 0.75hour, 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours | fluctuation |
| ilaprazole, aceclofenac Cmin,ss | Predose(0hour), after dose 0.5hour, 0.75hour, 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours | Minimum concentration of drug in plasma at steady state |
| ilaprazole, aceclofenac CLss/F | Predose(0hour), after dose 0.5hour, 0.75hour, 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours | Apparent clearance of drug in plasma at steady state |
Countries
South Korea
Outcome results
None listed